Scholarlink

Abstract <p>The objective of this study is to investigate the therapeutic effect of optogenetics on rat central post-stroke pain (CPSP) and the molecular mechanism. Total 27 rats were randomly divided into 3 groups – the sham surgery (Sham) group, the CPSP surgery (CPSP) group, and the CPSP with optogenetics (CPSP + NpHR) treatment group. The rats in CPSP + NpHR group received optogenetics treatment for 12 consecutive days after the surgery. The pain behavior test was performed to assess pain threshold of the rats. Immunofluorescence, immunohistochemistry, western blotting, and quantitative real-time polymerase chain reaction (RT-qPCR) was used to investigate the expression levels of pain-related factors c-Fos, vesicular glutamate transporter protein 2 (VGLUT2), and N-methyl-D-aspartate receptor subtype 2B(NR2B) in each group. <i>Results</i>: After optogenetics treatment for 12 days, the pain symptoms of the CPSP rats was improved, and the levels of c-Fos, VGLUT2, and NR2B in the M1 region of CPSP rats were significantly reduced. Furthermore, CPSP surgery resulted in increased pain sensitivity and overexpression of c-Fos, VGLUT2, and NR2B in rats, while optogenetics could reverse these abnormalities. Our results suggested that optogenetics could relieve pain in CPSP rats, and the therapeutic effect of optogenetics may attribute to reducing the expression of pain-related factors, such as c-Fos, VGLUT2, and NR2B.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Effect Analysis of Optogenetics on Rat Central Post-Stroke Pain

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月5日

查看全文
  • Chao Deng,
  • Ya-Yuan Gu,
  • TaoXu

摘要

Abstract

The objective of this study is to investigate the therapeutic effect of optogenetics on rat central post-stroke pain (CPSP) and the molecular mechanism. Total 27 rats were randomly divided into 3 groups – the sham surgery (Sham) group, the CPSP surgery (CPSP) group, and the CPSP with optogenetics (CPSP + NpHR) treatment group. The rats in CPSP + NpHR group received optogenetics treatment for 12 consecutive days after the surgery. The pain behavior test was performed to assess pain threshold of the rats. Immunofluorescence, immunohistochemistry, western blotting, and quantitative real-time polymerase chain reaction (RT-qPCR) was used to investigate the expression levels of pain-related factors c-Fos, vesicular glutamate transporter protein 2 (VGLUT2), and N-methyl-D-aspartate receptor subtype 2B(NR2B) in each group. Results: After optogenetics treatment for 12 days, the pain symptoms of the CPSP rats was improved, and the levels of c-Fos, VGLUT2, and NR2B in the M1 region of CPSP rats were significantly reduced. Furthermore, CPSP surgery resulted in increased pain sensitivity and overexpression of c-Fos, VGLUT2, and NR2B in rats, while optogenetics could reverse these abnormalities. Our results suggested that optogenetics could relieve pain in CPSP rats, and the therapeutic effect of optogenetics may attribute to reducing the expression of pain-related factors, such as c-Fos, VGLUT2, and NR2B.